New published evidence reinforces the importance of device choice in asthma control
Two new publications build on previous evidence that not all devices are equally effective in delivering asthma control. PLATTSBURGH, N.Y., Jan. 31, 2018 — A recent article in Pulmonary Pharmacology and Physiology1 provides in vitro evidence that the AEROCHAMBER PLUS® FLOW-VU® valved holding chamber (or spacer) delivers aerosolized drug more effectively than other chambers, a […]
Read the post:New published evidence reinforces the importance of device choice in asthma controlSignificant reductions in costly pulmonary complications with use of drug-free device
Post-operative pulmonary complications (PPCs) are a major burden to the healthcare system. A new real-world study published in Pulmonary Therapy, indicates significant reductions in costs when using the AEROBIKA® oscillating positive expiratory pressure (OPEP) device in the postoperative care setting.1 The retrospective database analysis including 288 patients undergoing cardiac, thoracic or upper abdominal surgery suggests that use […]
Read the post:Significant reductions in costly pulmonary complications with use of drug-free deviceMonaghan’s drug-free Aerobika® device helps reduce the real-world impact of exacerbations in chronic obstructive pulmonary disease
SYRACUSE, NY, 21 February, 2017 – Monaghan Medical Corporation (MMC) today announced the publication of a study in Pulmonary Therapy showing treatment with the Aerobika® device can significantly reduce the recurrence of exacerbations of COPD in the crucial 30-day period following hospitalization or emergency room visits.1 The study also showed that per-patient cost of exacerbations was significantly lower in the […]
Read the post:Monaghan’s drug-free Aerobika® device helps reduce the real-world impact of exacerbations in chronic obstructive pulmonary diseaseNew Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Shows Promise for Treatment of Bronchiectasis
SYRACUSE, NY, January 12, 2017 – Monaghan Medical Corporation (MMC) today announced that the findings of a study published in the most recent issue of Academic Radiology shows that patients with non-cystic fibrosis (CF) bronchiectasis responded favorably to airway maintenance therapy using the Aerobika® device. This latest study adds to the growing base of evidence that demonstrates Monaghan’s […]
Read the post:New Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Shows Promise for Treatment of BronchiectasisNew Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Reduces Acute Drug Usage And Costs Following COPD Exacerbations
Real-world study presented at CHEST 2016 Annual Meeting in Los Angeles SYRACUSE, NY, October 27, 2016 – Monaghan Medical Corporation (MMC) today announced that a new study presented to the American College of Chest Physicians (CHEST) shows MMC’s Aerobika® device is effective in reducing drug use for treatment of Chronic Obstructive Pulmonary Disease (COPD). COPD is a […]
Read the post:New Study Shows Monaghan Medical’s Drug-Free Aerobika® Device Reduces Acute Drug Usage And Costs Following COPD Exacerbations